Lung Cancer
Volume 64, Issue 2 , Pages 207-210 , May 2009

Carboplatin and pemetrexed in the management of malignant pleural mesothelioma: A realistic treatment option?

Received 19 April 2008 ,Revised 11 July 2008 ,Accepted 22 August 2008.

References 

  1. Bianchi C, Giarelli L, Grandi G, Brollo A, Ramani L, Zuch C. Latency periods in asbestos-related mesothelioma of the pleura. Eur J Cancer Prev. 1997;6(2):162–166
  2. Hodgson JT, McElvenny DM, Darnton AJ, Price MJ, Peto J. The expected burden of mesothelioma mortality in Great Britain from 2002 to 2050. Br J Cancer. 2005;92(3):587–593
  3. Peto J, Hodgson JT, Matthews FE, Jones JR. Continuing increase in mesothelioma mortality in Britain. Lancet. 1995;345(8949):535–539
  4. van Meerbeeck JP, Gaafar R, Manegold C, Van Klavaren RJ, Van Marck EA, Vincent M, et al. Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada. J Clin Oncol. 2005;23(28):6881–6889
  5. Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 2003;21(14):2636–2644
  6. Hughes A, Calvert P, Azzabi A, Plummer R, Johnson R, Rusthoven J, et al. Phase I clinical and pharmacokinetic study of pemetrexed and carboplatin in patients with malignant pleural mesothelioma. J Clin Oncol. 2002;20(16):3533–3544
  7. Castagneto B, Botta M, Aitini E, Spigno F, Degiovanni D, Alabiso O, et al. Phase II study of pemetrexed in combination with carboplatin in patients with malignant pleural mesothelioma (MPM). Ann Oncol. 2008;19(2):370–373
  8. Ceresoli GL, Zucali PA, Favaretto AG, Grossi F, Bidoli P, Del Conte G, et al. Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma. J Clin Oncol. 2006;24(9):1443–1448
  9. Hazarika M, White RM, Booth BP, Wang YC, Ham PY, Liang CY, et al. Pemetrexed in malignant pleural mesothelioma. Clin Cancer Res. 2005;11(3):982–992
  10. Niyikiza C, Hanauske AR, Rusthoven JJ, Calvert AH, Allen R, Paoletti P, et al. Pemetrexed safety and dosing strategy. Semin Oncol. 2002;29(6 Suppl. 18):24–29
  11. Hennessy BT, Gauthier AM, Michaud LB, Hortobagyi G, Valero V. Lower dose capecitabine has a more favorable therapeutic index in metastatic breast cancer: retrospective analysis of patients treated at M. D. Anderson Cancer Center and a review of capecitabine toxicity in the literature. Ann Oncol. 2005;16(8):1289–1296
  12. Fennell D, Steele J, Sheaff M. Response of malignant pleural mesothelioma to chemotherapy does not confer a survival advantage. Lung Cancer. 2005;49.(Suppl. 2):

PII: S0169-5002(08)00458-3

doi: 10.1016/j.lungcan.2008.08.016

Lung Cancer
Volume 64, Issue 2 , Pages 207-210 , May 2009

Article Tools

* Image Usage & Resolution